The 12 references in paper N. Syomash A., A. Belevsky S., N. Vyaz'menova I., Н. Сёмаш А., А. Белевский С., Н. Вязьменова И. (2014) “Возможности неантибактериальной терапии внебольничной пневмонии // Possibilities of non-antibacterial therapy of community-acquired pneumonia” / spz:neicon:pulmonology:y:2012:i:2:p:99-101

1
Синопальников А.И. Внебольничная пневмония у взрослых. Consilium medicum 2007; 9 (3): 3–8.
(check this in PDF content)
2
Rodriguez A., Lisboa T, Blot S. et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intens. Care Med. 2009, 35 (3): 430–438.
(check this in PDF content)
3
Siempos I.I., Vardakas K.Z., Korterides P., Falagas M.E. Adjunctive therapies for community-acquired pneumonia: a systematic review. J. Antimicrob. Chemother. 2008, 62 (4): 661–668.
(check this in PDF content)
4
Salluh J.I., Rovoa P., Soares M. et al.The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit. Care 2008; 12 (3): R76.
(check this in PDF content)
5
Авдеев С.Н. Осложнения внебольничной пневмонии. В кн.: Чучалин А.Г., Синопальников А.И., Чернеховская Н.Е. (ред.). Пневмония. М.: Экономика и информатика; 2002. 134–181.
(check this in PDF content)
6
Laterre P.F., Garber G., Levy H. et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit. Care Med. 2005; 33 (5): 952–961.
(check this in PDF content)
7
Nelson S., Belknap S.M., Carlson R.W. et al.A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment hospitalized patients with community-acquired pneumonia. J. Infect. Dis.1998; 178 (4): 1075–1080.
(check this in PDF content)
8
Root R.K., Lodato R.F., Patrick W. et al.Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit. Care Med. 2003; 31 (2): 367–373.
(check this in PDF content)
9
Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir. Res. 2005; 6: 82.
(check this in PDF content)
10
Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. BMC Pulm. Med. 2005; 5: 12.
(check this in PDF content)
11
Аляви А.Л., Курбанова Г.А. Состояние обмена оксида азота при включении N-ацетилцистеина в комплексную терапию больных внебольничной пневмонией. Пробл. туб. и бол. легких. 2007; 9: 20–24.
(check this in PDF content)
12
Авдеев С.Н., Батын С.З., Мержоева З.М., Чучалин А.Г. Высокие дозы N- ацетилцистеина при остром респираторном дистресс-синдроме. Пульмонология. 2010; 3: 31–38. Информация об авторах Сёмаш Наталия Александровна– младший науч. сотрудник отдела
(check this in PDF content)